What's in a name? US FDA mulls unique versus same for biosimilars
This article was originally published in SRA
Executive Summary
Among the issues that cropped up throughout an 11 May all-day US Food and Drug Administration meeting was whether biosimilars should share the same international nonproprietary name (INN) as the innovator biologics on which they are based or whether they should have unique names1.